Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Mesalamine for colorectal cancer preventionpProgramme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome: a study protocol
Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden; Dept. of Medicine, Ersta Hospital, Stockholm, Sweden.
Dept. of Medicine, Ersta Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Copenhagen University Hospital, Copenhagen, Denmark.
Dept. of Surgery, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska Academy, Västra Götaland County, Gothenburg, Sweden.
Show others and affiliations
2025 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 15, no 11, article id e100082Article in journal (Refereed) Published
Abstract [en]

Introduction: Lynch syndrome (LS) carriers have a 20-46% lifetime risk of colorectal cancer (CRC) due to mismatch repair gene variants. Mesalamine (5-ASA, 5-aminosalicylic acid), used safely in patients with ulcerative colitis, may reduce CRC risk in LS by decreasing microsatellite instability, a key driver of LS-related cancer. This study evaluates 5-ASA's efficacy as a tolerable chemopreventive drug, aiming to improve long-term CRC prevention in LS.

Methods and analysis: This multicentre, multinational, randomised, double-blind, two-arm, phase II clinical study will compare the effects of a 2-year daily intake of 5-ASA (2000 mg) to placebo in LS carriers. The primary objective is to assess whether mesalamine reduces colorectal neoplasia, both benign and malignant, compared with placebo in LS carriers, as detected by colonoscopy at the end of the treatment period (24 months±1 month) and on study completion. Secondary objectives include evaluating whether 5-ASA reduces neoplasia/tumour multiplicity and progression compared with placebo at specified time points, examining variations in the effects of 5-ASA versus placebo based on cancer history, sex and age (<45 years vs ≥45 years), and assessing the safety of 5-ASA in LS carriers.

Ethics and dissemination: The trial is currently open for enrolment, having received ethical approval from the Regional Ethical Review Board in Stockholm and funding from the Swedish Research Council. The study protocol is the finalised V.10.0 (11 April 2024), transitioned to the European Clinical Trials Information System. LS remains underdiagnosed, which may limit recruitment. The results are of global interest and will be published in peer-reviewed journals and presented at scientific conferences.

Trial registration number: ClinicalTrials.gov: NCT04920149. EudraCT: 2019-003011-55. EU CT: 2024-514765-19-01.

Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2025. Vol. 15, no 11, article id e100082
Keywords [en]
Clinical Protocols, Clinical trials, Endoscopy, Gastrointestinal tumours, Microbiota
National Category
Gastroenterology and Hepatology Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-246787DOI: 10.1136/bmjopen-2025-100082ISI: 001612842000001PubMedID: 41213710Scopus ID: 2-s2.0-105021459283OAI: oai:DiVA.org:umu-246787DiVA, id: diva2:2016698
Funder
Swedish Research Council, 2017-00557Swedish Cancer Society, 21 1500 FkSwedish Cancer Society, 22 2294 PjSwedish Cancer Society, 24 0821 FkRegion Stockholm, FoUI-988411Region Stockholm, FoUI-974948Available from: 2025-11-26 Created: 2025-11-26 Last updated: 2025-11-26Bibliographically approved

Open Access in DiVA

fulltext(971 kB)59 downloads
File information
File name FULLTEXT01.pdfFile size 971 kBChecksum SHA-512
d1eb6b2a971e52a557d3fc54fde6e43a7703cba7606883f070bd13491fd90a1bf395027625fc28a4b18a40a5d14929b4e3d894e052ab4eaa80a02a16ffcdfb73
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Silander, Gustav

Search in DiVA

By author/editor
Silander, Gustav
By organisation
Department of Diagnostics and Intervention
In the same journal
BMJ Open
Gastroenterology and HepatologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 60 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 365 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf